Company

photopharmics.com

Rocket Ship Rating

Rocket Ship Rating: 94 out of 100

Advancing Investigational Photo Neuromodulation for Parkinson’s Disease

Also known as PhotoPharmics

Medical devices & diagnostics
Hardware

Status: Operatingas of 2026-09-19
Business model: B2B

Open relationship map

Claim, correct or request removal

Record updated 28 September 2026

About

PhotoPharmics, a clinical-stage medical device company developing photo-neuromodulation therapies for neurodegenerative diseases

Funding snapshot

Total raised: $44.8MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
Latest round: Round, $26.2M2023-10-31

Funding rounds

Round, 2023: $26.2M2023-10-31, SEC form D sold, 47 investors
Round, 2020: $2.5M2020-12-04, SEC form D sold, 9 investors
Round, 2019: $6.6M2019-09-27, SEC form D sold, 24 investors
Round, 2017: $2.7M2017-02-24, SEC form D sold, 18 investors
Round, 2017: $2.3M2017-01-31, SEC form D sold, 15 investors
Round, 2015: $2.1M2015-06-12, SEC form D sold, 15 investors
Round, 2012: $2.1M2012-12-27, SEC form D sold, 13 investors
Round, 2012: $330K2012-10-31, SEC form D sold, 7 investors

Products

Hardware: Celeste®